Liraglutide 3.0 mg works safely and effectively for weight loss in different racial groups

Weight loss with liraglutide 3.0 mg was statistically significant across all racial subgroups, with an average loss of 7.7% for white participants.

• Liraglutide 3.0 mg was associated with significant mean weight loss compared to placebo in white (7.7% vs. 2.3%), black/African-American (6.3% vs. 1.4%), Asian (6.3% vs. 2.5%), and other (7.3% vs. 0.49%) participants.
• The treatment effects on weight and cardiovascular risk markers did not show dependence on race, as indicated by statistical tests.
• Adverse events were similar across all racial subgroups, suggesting a consistent safety profile.

Simplified